Hatfield Jeffrey S. 4

What Happened
Jeffrey S. Hatfield, a director of Vir Biotechnology (VIR), was granted two awards on May 27, 2026: 8,000 restricted stock units (RSUs) and a 16,000-share derivative award (stock option-type award). Both grants show a $0.00 purchase price on the Form 4 (no cash paid). According to the filing footnotes, the RSUs and the derivative award will vest in full on May 27, 2027.

Key Details

• Transaction date: 2026-05-27; Filing date: 2026-05-28 (filed timely).
• Grants: 8,000 RSUs (F1) and a 16,000-share derivative award/option (A, derivative). Both reported at $0.00 acquisition price.
• Vesting: RSUs vest in full on May 27, 2027 (F2); the derivative award/option will vest and become exercisable in full on May 27, 2027 (F3).
• Shares owned after the reported transactions: not stated in the supplied filing details.
• No sale or exercise occurred — these are awards/vesting grants, not purchases or market sales.

Context
Grants of RSUs and option-type awards are common compensation/retention tools for executives and directors. Because these awards vest in a year, they are intended to tie the director to future company performance rather than signal immediate buying or selling. The filing shows acquisition at $0.00 (standard for equity awards) and was filed promptly the next day.